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A Chlamydia trachomatis é responsável por uma das infecções bacterianas 
sexualmente transmissíveis mais comuns na Europa e nos EUA. Esta bactéria Gram 
negativa é um patogénico intracelular obrigatório, com um ciclo biológico bifásico, no 
qual se observam duas morfologias bacterianas diferentes, o Corpo Elementar (CE) e o 
Corpo Reticular (CR). As formas infectantes desta bactéria são os CEs que têm 
capacidade de se agregar e invadir as células dos mamíferos. Este processo parece ser 
dependente do Sistema de Secreção Tipo III (T3SS), permitindo a secreção de efectores 
de Chlamydia para as células do hospedeiro, os quais modulam o esqueleto de actina 
das células eucariótas promovendo a invasão. Um dos primeiros efectores secretados 
pela Chlamydia designa-se TarP (Translocated Actin Recruiting Protein). Efectores 
ortólogos ao TarP estão presentes em todas as espécies do género Chlamydia. Estes 
ortólogos apresentam polimorfismos associados com alguns subdomínios, como é o 
caso o domínio rico em tirosina, que apenas se encontra presente no TarP descrito para 
C. trachomatis. Apesar das diferenças verificadas nos ortólogos das diferentes espécies 
de Chlamydia, todos têm a capacidade de recrutar e agregar actina permitindo a 
internalização da bactéria por parte da célula. Uma vez que, numa fase inicial da 
invasão, a secreção do TarP parece ser indispensável para a mesma, poderia pensar-se 
que, para que esta secreção seja eficiente, deve ser facilitada por uma chaperona do 
T3SS. Estas chaperonas são, normalmente, proteínas de baixo peso molecular (13-16 
kDa), com um ponto isoeléctrico acídico e uma estrutura secundária com um motivo    
α-β-β-β-α-β-β. Através do estudo da estrutura secundária previram-se três chaperonas 
do T3SS, CT043 (Slc1), CT663 (Slc2) CT088 (Scc1), presentes em CEs de Chlamydia. 
A interacção destas chaperonas com o domínio N-terminal do TarP (aa 1-200) testou-se 
através de ensaios de co-imunoprecipitação. Observou-se que, das três chaperonas 
testadas, o TarP unicamente interage de forma específica com a chaperona Slc1. Tendo 
como base estes resultados, utilizou-se um ensaio de duplo híbrido para avaliar quais os 
efeitos que mutações a nível do N-ternimal do TarP (1-100) têm na sua interacção com 
Slc1. Este estudo teve como objectivo identificar os aminoácidos que estão envolvidos 
na ligação do TarP à chaperona Slc1. Através da utilização de diversos mutantes no     
N-terminal do TarP, concluiu-se que a interacção entre o TarP e Slc1 parece depender 








Chlamydia trachomatis is the most common cause of sexually transmitted 
bacterial infection in Europe and in the United States. It is a Gram negative obligate 
intracellular pathogen with a unique biphasic development cycle, possessing two 
distinct morphological forms, the elementary body (EB) and the reticulate body (RB). 
The EBs are the infectious form and are able to attach and invade mammalian cells. 
This process is likely dependent on the Type III Secretion System, which allows 
secretion of Chlamydia effectors that modulate the actin skeleton of the host cell and 
promote invasion. One of the first effectors to be secreted is TarP (Translocated Actin 
Recruiting Protein). Orthologs of this effector are present in all Chlamydia with some 
polymorphisms associated with some subdomains. An example is the tyrosine rich 
domain, which is only present in the TarP homolog of the C. trachomatis species. 
Despite this difference, all chlamydial TarP are able to recruit and nucleate actin to 
promote the internalisation of Chlamydia. Since early secretion of TarP is crucial for 
invasion it was hypothesized that this secretion, in order to be efficient must be 
facilitated by a Type III Secretion chaperone. These usually are small proteins (13-16 
kDa) with an acidic pI and a secondary structure motif of α-β-β-β-α-β-β. Three putative 
Chlamydia trachomatis Type III secretion chaperones, CT043 (Slc1), CT663 (Slc2), 
CT088 (Scc1), which are present in EBs have been predicted by their secondary 
structures. The interaction of these chaperones with the N-terminal domain of TarP 
(amino acids 1-200) was tested using pull-down assays.  A specific interaction between 
TarP and Slc1 was observed, but not with Slc2 or Scc1. Using a bacterial two-hybrid 
assay, we evaluated the effects of mutating TarP(1-100) on its interaction with Slc1. 
The objective was to identify critical amino acid residues involved in chaperone 
binding. Using several mutants TarP derivatives, we were able to conclude that the 











I would like to show my gratitude to my mentor Rey Carabeo, who surpassed 
my expectation in every way, greatly contributing for my development as a scientist and 
creating optimal work environment. I would also like to thank him for the promptitude 
in the correction and guidance on my written work, which was invaluable. 
Furthermore I also like to thank all the former and Current Lab member: 
Amanda Brinkworth for the initial guidance in the laboratory and for providing the 
mutants for my thesis; David Banbury for his friendliness, making me feel more 
relaxed, for his exchange of ideas about the projects and his patience in showing me 
how electronic microscopy works; Chris Thompson for being a constant source of 
knowledge and help whenever I had any doubt and/or problem in a method even after 
finishing his PhD in Imperial and starting a new job; Tristan Thwaites for his sense of 
humour shown especially outside the work environment; and Denise Malcolm for her 
priceless help in the laboratory work, with a special thank, for the help with the pull-
down assay. 
I specially want to thank my mother and sister for their support and opinion on 
the thesis. 
Finally, I would like to acknowledge Ana for whom a simple thank you is not 
enough, for her incredible patience, support, for her exchange of ideas on the project, 



















Resumo         iii 
Abstract         v 
Acknowledgements        vii 
List of figures         xi 
List of tables         xiii 
List of abbreviations         xv 
Introduction         1 
Materials and Methods       7 
Results and Discussion       14 
 Determination of interaction between TarP and  
Type III chaperones from Chlamydia    14 
 Determination of binding site between effector TarP and  
chaperone Slc1       19 
General conclusion        33 
Future work         36 
Annex          xvii 
















List of figures 
 
Page 
1. A schematic representation of the Chlamydial developmental cycle. 2 
2. Co-imunoprecipitation, NiNTA agarose beads, α-6xHis.   15 
3. Co-imunoprecipitation, NiNTA agarose beads, α-FLAG.   16 
4. Co-imunoprecipitation, M2 affinity gel, α-6xHis.    17 
5. Co-imunoprecipitation, M2 affinity gel, α-FLAG.    18 
6. Schematic of Principle of an E. coli two-hybrid system based on  
 functional complementation of CyaA fragments.    20 
7. Analyzes of pUT18C digestion to confirm the functionality of KpnI 22 
8. mTarP 1 confirmation in Top10.      23 
9. mTarP 2 confirmation in Top10.      23 
10. mTarP 3 and 4 confirmation in Top10.     23 
11. mTarP 5 confirmation in Top10.      24 
12. mTarP 6 confirmation in Top10.      24 
13. mTarP 7 confirmation in Top10.      24 
14. mTarP 8 confirmation in Top10.      25 
15. Slc1 confirmation in DHM1.       26 
16. mTarP 1 confirmation in DHM1.      26 
17. mTarP 2 confirmation in DHM1.      26 
18. mTarP 3 confirmation in DHM1.      27 
19. mTarP 4 and 5 confirmation in DHM1.     27 
20. mTarP 6 confirmation in DHM1.      27 
21. mTarP 7 confirmation in DHM1.      28 
22. mTarP 8 confirmation in DHM1.      28 
23. Bacterial two-hybrid assay.       29 











List of tables 
 
Page 
Strains and plasmids used in this study     12 



























List of abbreviations 
 
 
Actin Binding Domain: ABD 
Chaperone-binding Domain: CBD 
Dimethyl Sulfoxide: DMSO 
Elementary Body: EB 
Enteropathogenic E. coli: EPEC 
Kilobase: kb 
Luria-Bertani: LB Broth  
Phosphate-buffered Saline: PBS 
Phosphor-inositol 2,3,4,5-P3: PIP3 
Polymerase Chain Reaction: PCR 
Polyvinylidene Difluoride: PVDF 
Reticulate Body: RB 
Sodium Dodecyl Sulphate-polyacrylamide Gel Electrophoresis: SDS-PAGE 
Specific Chlamydia Chaperone 1: Scc1 
Src-homology 2 Domain: SH2 
SycE like Chaperone 1: Slc1 
SycE like Chaperone 2: Slc2 
Translocated Actin Recruiting Phosphoprotein: TarP 












Pathogenic Chlamydia species can invade human mucosal epithelial cells and 
cause a diverse number of diseases. C. pneumoniae can infect the majority of humans 
and cause mild cases of pneumonia in adults and serious respiratory disease can occur in 
developing countries and in hospitalized individuals. Chronic infection is associated 
with an enhanced risk of developing atherosclerotic, cerebrovascular and chronic lung 
diseases. C. psittaci, more recently named Chlamydophila caviae (GPIC), is commonly 
found among avian species, although it is a highly infectious agent, its infections in the 
wild only affects a small fraction of birds at a given time. In humans it can cause 
psittacosis, which is a form of pneumonia associated with high risk groups. Chlamydial 
infections are also endemic to many mammals, such as koalas, guinea pigs, mice, sheep, 
and cattle (Darville and Hiltke 2010; Schachter, 1999). 
Chlamydia trachomatis is a Gram negative obligated intracellular pathogen it is 
the most common sexually transmitted bacterial infection in Europe and in the United 
States, making it an enormous world public health problem. More than 343 thousand 
cases were reported in EU/EEA in 2009, and of those, approximately two thirds were 
reported among individuals between 15 and 24 years of age. Still this number is greatly 
underestimated due to the few countries that report the cases and because two thirds of 
the infections have few or no symptoms.  
Long-term infection of C. trachomatis can lead to severe complications, which 
depends on the serovar responsible for the infection. C. trachomatis serovars D-K 
infection can result in cervicitis, urethritis, salpingitis and proctitis. C. trachomatis 
serovars LGV1-3 are responsible for invasive genital infections, which can cause 
lymphogranuloma venereum. Infections with serovars A-C result in chronic 
conjunctivitis, which can progress to blinding trachoma preventable blinding condition 
(ECDC, 2011; Schachter, 1999; WHO 2011). 
A main difference between chlamydial species and other intracellular bacteria is 
its unique biphasic development cycle in which Chlamydia alternates between two 
morphological forms, the elementary body (EB) and reticulate body (RB) (Figure 1). 
EBs are metabolically inert forms, responsible for the dissemination of infection due to 
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their ability to attach and invade susceptible cells. After attachment EBs are internalized 
in membrane bound vacuoles named inclusions. EBs differentiates into metabolically 
active forms, termed RBs, and undergoes repeated cycles of binary division 
(AbdelRahman and Belland, 2005). Cultures are reasonably synchronous until 
proliferating RBs begin to convert asynchronously to EBs. This conversion occurs at 
18–20 hours post infection for C. trachomatis L2 (Moulder, 1991). The host cell then 
lyses, releasing EBs, which infect neighbouring cells. Under imposed stressful growth 
conditions, such as the presence of antibiotics and nutrient deprivation the normal 
Chlamydia development cycle is disrupted, leading to the appearance of large, aberrant 
RBs (AbdelRahman and Belland, 2005). 
The EBs have been linked to a “spore-like” form of the organism. It has a highly 
compact nucleoid, which is delocalized within the cell body, suggesting an association 
with bacteria inner membrane or cell wall. Unlike other gram-negative bacteria, 
Chlamydial EBs have little to no peptidoglycan present in the cell wall. Instead the 
structural rigidity is thought to be due to a highly cross-linked cysteine rich protein in 

















Electron microscopic examination of EBs using high pressure freezing has 
showed spike-like hexagonally organized structures on the surface of EBs. Several 
authors have speculated that this projections correspond to the T3SS (Type III Secretion 
System) “needle structures”, similar to those found in other gram-negative bacteria like 
Salmonella enterica serovar typhimurium, EPEC (Enteropathogenic E. coli), Yersinia 
and Pseudomonas. All this bacteria have several types of bacterial secretion systems 
already described but only one actively transports proteins directly from the bacteria 
cytosol to the host cell cytosol (Büttner and Bonas, 2002). This system, Type III 
Secretion System (T3SS), consists of a needle complex with a cylindrical structure, and 
a basal structure associated to the bacterial membrane. The needle complex crosses the 
inner and outer bacterial membrane, and it extends itself to the extracellular space and 
upon contact with the target cell, effectors/translocators are secreted and form a pore 
that connects with the needle (Cornelis, 2006).  
Conclusive evidence has not yet been found to confirm these hypotheses but 
Fields et al. (2003) have shown that inclusion membrane protein genes (inc gene) are 
expressed early in the development cycle, much earlier than the genes encoding 
components of the T3SS. They have also verified that these proteins appeared in the 
inclusion membrane before the proteins were produced. These proteins were shown to 
be T3SS substrates in the heterologous Yersinia system. This strongly supports the 
conclusion of a pre-formed T3SS in EBs (AbdelRahman and Belland, 2005). 
Clifton et al. (2004) have shown that, immediately after the irreversible binding 
step between the bacteria and the host cell, a T3SS exported effector is translocated to 
the host cell. This protein is named CT456 or Translocated Actin Recruiting 
Phosphoprotein (TarP). It contains variable copies of the ENIYE tandem repeat motifs 
of approximately 50 amino acids in the N-terminal half of the protein. Within this 
repeats there are tyrosine residues which are phosphorylated upon entry by host cell 
kinases and is both spatially and temporally associated with the recruitment of actin at 
the EB site of entry (Clifton et al., 2004; Clifton et al., 2005; Jewett et al., 2008). 
TarP orthologs are present in all Chlamydia species examined to date. The 
alignment analysis of the orthologs from C. trachomatis serovars L2 and D, C. 
muridarium, C. caviae and C. pneumoniae indicated that only Chlamydia trachomatis 
ortholog possessed the tyrosine rich domain and further studies revealed that it is also 
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the only one in which phosphorylation occurs. Despite all Chlamydia species 
demonstrated actin recruitment to the invasion site, suggesting that TarP 
phosphorylation is not require for actin recruitment (Clifton et al., 2004; Clifton et al., 
2005). 
Ectopic expression of full-length TarP as well as of the N-terminal, and             
C-terminal domains confirmed tyrosine phosphorylation of the full-length protein as 
well as of the isolated N-terminal region (Clifton et al., 2005). 
TarP is able to associate directly with both monomeric actin and filamentous 
actin, independently of phosphorylation confirming earlier findings and explaining the 
absence of this domain in the majority of Chlamydia species. Through the comparison 
of C. trachomatis L2 TarP ortholog and known actin nucleator proteins it was 
discovered a similar sequence between this effector and the actin binding domain 
(ABD) of WH2-family proteins (Jewett et al., 2006). The number of ABD varies 
between TarP orthologs. 
The tyrosine residues present in TarP can be phosphorylated by a wide variety of 
host cell tyrosine kinase containing the Src-homology 2 domain (SH2). Scr, Yes, Fyn, 
Syk and Ab1 are host cell kinases that have the SH2 domain and all are able to 
phosphorylate the C. trachomatis TarP residues (Elwell et al., 2006; Jewett et al., 2008; 
Mehlitz et al., 2008). Furthermore, it was observed that individual knockdowns of each 
kinase did not completely inhibited tyrosine phosphorylation. This has also been 
described for other T3SS effectors, from other gram negative bacterial, EPEC effector 
Tir and Helicobacter pylori CagA, which are all substrates of different kinase of the cell 
host. Despite of this common promiscuity between effectors and host cell tyrosine 
kinase the effects of phosphorylation in the function of these proteins vary. In the case 
of Tir the phosphorilation is necessary in order to activate its function as an actin-
nucleator whereas in the case of CagA this phosphorilation is necessary in order for it to 
induce cytoskeleton changes (Mehlitz et al., 2008). 
In Chlamydia trachomatis the phosphorylated tyrosine residues of effector TarP 
have been shown to be able to recruit the guanine nucleotide exchange factors Sos-1 and 
Vav-2 (Carabeo et al., 2007; Lane et al., 2008). This factors form a complex with PIP3 
(phosphor-inositol 2,3,4,5-P3) and Abi-1, which can activate Rac in a phosphotyrosine 
dependent manner. Rac can recruit actin by the involvement of Abi-1 and WAVE-2 
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dependent formation of the actin-recruitment Arp 2/3 complex (Carabeo et al., 2007). 
Every Chlamydial TarPs have proline rich domains that promote TarP aggregation and 
the ABD that is capable of nucleating actin (Jewett et al., 2006). It has been proposed 
that the ABD on TarP may further contribute for the polymerization of actin filaments 
already induced by Arp2/3 complex (Carabeo et al., 2007). 
Phosphorylation of CT456 does not appear to be important for this protein 
activity as an actin nucleator or for the invasion of non-phagocytic cells by Chlamydia. 
However, it has been shown by Mehlitz et al. (2010) that TarP phosphorylation up 
regulates the host cell MEK/ERK pathway thereby activating the protein SHC1. This 
pathway is important for host cell survival, and it’s activation by Chlamydia effector 
TarP prevents host cell apoptosis. 
T3SS secreted effectors and components usually require chaperones to be 
efficiently translocated. These chaperones that mediate the translocations of T3SS 
effectors are termed Class I chaperones. They are typically small (13-16 kDa), usually 
dimers that have a relatively acidic pI (4-5) and have a very distinct secondary structure, 
α-β-β-β-α-β-β (Brinkworth, 2011; Cornelis, 2006; Kim, 2001; Peters et al., 2007) 
(Annex A1). These chaperones are known to have multiple roles including 
stabilization/antiaggregationn, maintenance of secretion-competent state, targeting of 
the translocation translocation apparatus and conferring temporal hierarchy in secretion 
and regulation (Page and Parsot, 2002). Also they interact with their cognate effector 
chaperone-binding domain (CBD), with hydrophobic surface, present in the first 100 
amino acids. It should be mentioned that only a few known T3SS chaperones are able to 
bind to multiple effectors, Spa15 (Shigella spp.), InvB (S. typhimutium) and CesT 
(EPEC), which suggests that the CBD is not simply the presence of a hydrophobic 
domain (Brinkworth, 2011). The chaperone CT043-Specific Chlamydia Chaperone 1 
(Slc1), previously predicted has a T3SS chaperone, was recently identified and 
confirmed as being a binding partner of TarP, by bacterial 2-hybrid, pull-down and 
translocation assays.  
In this project it was hypothesized that the binding between the T3SS effector 
TarP and the chaperone Slc1 is sequence-specific, similar to what is observed in other 
T3SS-harbouring bacteria. While the binding of Slc1 to TarP may depend on the 
hydrophobic interactions of the N-terminal domain of TarP with the binding pocket 
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produced by Slc1 dimers, the interaction may also display a greater specificity conferred 
by a specific sequence of amino acids.   
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Materials and Methods 
 
Culture 
Escherichia coli strains were stocked in LB Broth (Luria-Bertani) containing 
30% of glycerol at –80 ºC.  Initial overnight cultures were performed in LB medium 
with the appropriate antibiotics (100 μg/ml of Carbenicillin and/or 60 μg/ml of 
Kanamycin) and incubated at 37 ºC with agitation (200 rpm). 
For the bacterial 2-hybrid assays the E. coli DHM1 overnight cultures were 
inoculated in LB agar with the appropriate antibiotic plus 40 µg/ml of X-gal and 1 M of 
IPTG, 10 μl of overnight culture using the drop technic, incubated overnight at 37 ºC, 
them they were left at room temperature to allow the development of colour for a 
maximum of 72 hours. 
For the pull-down assay the E. coli TOP 10 overnight culture was dilute 1:33 
into 10 ml of LB with Kanamycin (60 μg/ml) and Carbenicillin (100 μg/ml) and 
incubated at 37 ºC with agitation (200 rpm) to an optic density at 600 nm (OD600) of 
0,4-0,65. At this time, in order to induce the expression of the proteins, 1mM of IPTG 
was added and the culture was incubated at 37 ºC with agitation (200 rpm). 
 
Polymerase Chain Reaction (PCR) 
The primers used for PCR experiments as well as the conditions used for the 
PCR reaction are listed in Table 2.   
For cloning mTarP100aa sequences obtained, the DNA Polymerase with proof 
reading Accuprime PFX polymerase supermix (Invitrogen Life Technologies) was used. 
The temperature used for the PCR cycle followed the instructions provided by the 
manufacturer. The cycle used for polymerase activation was 95 ºC for 5 minutes 
followed by 31 cycles with the following steps: denaturation at 95 ºC for 15 seconds, 
annealing at lowest primer temperature minus 5 ºC (calculated using Integrated DNA 
Technologies) for 30 seconds and elongation phase at 68 ºC, 1 minute per kilobase (kb). 
After the 31 cycles were completed a final extension set was added, 68 ºC 5 minutes, to 
prevent incomplete DNA sequences. 
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The PCR fragments were analysed by electrophoresis on 1,5 % agarose gel and 
SYBR Safe (Invitrogen, Life Technology) staining was performed in order to visualize 
the DNA fragments obtained. 
To confirm the presence of inserts encoding the mTarP100aa sequences in 
pUT18c and pKT25 and for the confirmation of positive colonies containing the 
sequences a PCR assays were used according to the instructions provided by the 
manufacturer for the PCR supermix (Invitrogen Life Technologies). The conditions 
used were polymerase activation at 95 ºC for 5 minutes followed by 31 cycles with the 
following steps: denaturation at 95 ºC for 20 seconds, annealing at lowest primer 
temperature minus 5 ºC (calculated using Integrated DNA Technologies) for 30 seconds 
and elongation phase at 72 ºC, 1 minute per kb. After the 31 cycles were completed a 
final extension set was added, 72 ºC for 5 minute, to prevent incomplete DNA 
sequences. The PCR fragments obtained were analysed as previously described. 
 
PCR Fragments Purification or Extraction Kit  
Purification of PCR DNA products obtained was performed using QIAquick Kit 
(Qiagen) following the manufacturers recommendation in “QIAquick PCR Purification 
Kit Protocol” or “QIAquick Gel Extraction Kit Protocol” depending on whether the 
PCR amplicons were purified directly or by gel extraction, respectively. 
 
Plasmids purification 
Plasmid DNA was purified from E. coli Top10 genetically modified strains 
using Qiaprep Spin Miniprep Kit, following manufactures instructions (Qiagen). 
 
Restriction Enzyme Digestion  
Restriction enzyme digestion was performed using 2 μl of NEB2 buffer 10x 
(New England Biolabs), 2 μl of BSA 10x, 1 μl of KpnI restriction enzyme and 10 μl of 
PCR insert or plasmid in a final volume of 20 μl. Restriction enzyme reaction was 
performed at 37 ºC for 3 hour, followed by 15 minutes at 65 ºC for deactivation of the 
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enzymes. A small amount of cut plasmid and uncut was analysed using electrophoreses 
in a 1 % agarose gel to guarantee the functionality of the restriction enzymes. 
 
Determination of Plasmids and Insert Concentration  
DNA concentration was measured on NanoDrop UV-Vis spectrophotometer 
(NanoDrop®) was used, using 1 μl of each sample (PCR insert or plasmid).  
 
Ligation  
The ligation between the insert and the plasmid vector was accomplished using 
T4 ligase (New England Biolabs). The ratio used was 3:1 insert:vector with total 
amount of DNA ranging between 10 and 100 ng. To achieve ligation, 1 μl of T4 ligase 
enzyme and 1 μl of the corresponding buffer 10x in a final volume of 10 μl were used. 




Preparation of chemically competent E.coli Top10 
Wild type strains of E. coli Top10 were inoculated, using a glycerol stock, in 
5ml SOB medium (5 g of NaCl, 20 g of tryptone, 5 g yeast extract, 2,5 ml of 1M KCl 
solution in 1L of double distilled water (ddH2O)) and incubated overnight at 18 ºC with 
agitation (200 rpm). The following day OD600 was measured, when it reached a value 
between 0,4-0,45 the cultures were put on ice. Using pre-cooled 50 ml falcon tubes the 
cultures were centrifuge at 4000 rpm for 30 min at 4 ºC. Afterwards the supernatant was 
discard and the pellet was resuspended  in 15 ml of ice-cold Inoue solution (10,9 g of 
MnCl2, 2,2 g of CaCl2, 18,7 g of KCl, 20 ml of 0,5 piperazine-1,2-bis-ethanesulfonic 
acid, in 1 L of ddH2O). Repeat the centrifugation; discard the supernatant and 
resuspension of the pellet in 20ml of ice-cold Inoue Solution, twice. Without discarding 
the supernatant 1,5 ml of dimethyl sulfoxide (DMSO) was added to the 20 ml of cell 
suspension and incubated on ice for 10 min. The cell suspension was then divided in 
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100 µl aliquots in precooled, sterile 1,5 ml eppendorfs, froze using liquid nitrogen and 
stored at -80 ºC until used. 
 
Heat shock transformation 
DNA (between 1 and 10 μl of insert-plasmid) was mixed with 100 μl of 
chemically competent bacterial cells and homogenized gently before incubating on ice 
for 30 minutes. A heat-shock was performed for 45 seconds at 42 ºC followed by 10 
minutes on ice. Bacteria were then incubated with 250 μl of SOC medium, at 37 ºC with 
agitation (200 rpm) for 1 hour. 100 μl of bacterial suspension was plated in LB agar 
with the appropriate antibiotic and incubated overnight at 37 ºC. 
 
Preparation of electrocompetent cells 
E. coli DHM1 overnight cultures in 5 ml of LB medium incubated at 37ºC with 
agitation (200 rpm) were pelleted by centrifugation (15 minutes, 4000 rpm at 4ºC). 
Bacterial pellet was resuspended in 1ml of sterile cold 10% glycerol solution. The 
previously mentioned steps were repeated five times. After the last centrifugation, the 
bacterial pellet was resuspended in 1 ml of sterile cold 10% glycerol, and divided in   
100 µl aliquots. 
 
Transformation by electroporation 
After the preparation of electrocompetent cells each aliquot of electrocompetent 
bacteria were mixed with 1 to 10 µl of insert-plasmid. Electroporation was performed 
using Gene Pulser II (Biorad) using the following conditions: 25 µFD, 200 Ω, and    
1,80 kV; Immediately after electroporation, 300 µl of SOC medium were added and the 
bacteria were incubated for 1 hour at 37 ºC with agitation (200rpm). The bacterial 
suspension was plated on LB agar plates containing the appropriate antibiotic and 






Overnight culture grown in LB with kanamycin and carbenicillin was diluted by 
1:33 into 10 ml of the same medium and grown until OD600 between 0,4-0,65. After 
protein induction with 1 mM of IPTG for 3,5 hours, bacteria were centrifuged at      
4000 rpm for 30 minutes. The supernatant was discarded and the pellets were stored at -
20 ºC overnight. The following day the pellets were thawed and for the HIS-tag pull-
down it was used the QIAexpressionist protocol 9 “Preparation of cleared E. coli lysate 
under native conditions” and 11 “Preparation of 6xHis-tagged periplasmic proteins from 
E. coli” (Qiagen). For the FLAG pull-down anti-FLAG M2 affinity gel was use 
following manufactures instructions. 
 
Western blotting 
Electrophoretic Transfer to PVDF Membranes  
Specific secreted proteins were identified by Western blotting analysis. Secreted 
proteins separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) were transferred to a polyvinylidene difluoride (PVDF) membrane. The 
transfer was perfomed at 180 mA for one hour.  
After transfer, the membrane was saturated for 1 hour in phosphate-buffered 
saline (PBS) containing 5% non-fat milk.  
The membrane was then incubated with the primary antibody (1/200 dilution of 
rabbit polyclonal anti-TarP (kindly provided by Dr. Raphael Valdivia, Duke University 
Medical Center) for 1 hour at room temperature followed by three washes with PBS 
0,1% Tween (5 minutes each at room temperature). The membrane was, then, incubated 
with the secondary antibody (1/2000 dilution of anti-rabbit peroxidase, Jackson 
Immunoresearch Laboratoires) for 1 hour at room temperature followed by three washes 
with PBS 0,1% Tween (5 minutes each at room temperature).  
Detection of chemiluminescence was performed using the “Immobilon
TM
 
Western chemilominnescent HRP Substrate” kit from Millipore. The kit is composed by 




Table1: Strains and plasmids used in this study 
Strains Characteristics Reference 
Top10 E.coli high-level propagation 
Invitrogen Life 
Technologies 
BL21star E.coli high-level expression 
Invitrogen Life 
Technologies 
DHM1 Adenylate cyclase deficient E.coli Karimova, 1998 
Plasmids   
pUT18C 




E.coli 2-hybrid vector - cya fragment 25 fusion Kanamycin 
resistance 
Karimova, 1998 
pUT18C - TarP100 E2H -cya-18 fragment fused to Nterm 100aa TarP L2 This study 
pUT18C - ΔTarP1 
E2H -cya-18 fragment fused to Nterm 100aa TarP L2 
(Ser17Thr, Ser23Thr) carbenicillin resistance 
This study 
pUT18C - ΔTarP2 
E2H -cya-18 fragment fused to Nterm 100aa TarP L2 
(Gln9His, Ser26Tyr, Asn39Ile, Ser56Pro, Ile57Asn, 
Asn66Leu) carbenicillin resistance 
This study 
pUT18C - ΔTarP3 
E2H -cya-18 fragment fused to Nterm 100aa TarP L2 
(Gln44Leu, Thr68Ala) carbenicillin resistance 
This study 
pUT18C - ΔTarP4 
E2H -cya-18 fragment fused to Nterm 100aa TarP L2 
(Gln44Leu) carbenicillin resistance 
This study 
pUT18C – ΔTarP5 
E2H -cya-18 fragment fused to Nterm 100aa TarP L2 
(Thr13Ser, Ser21Thr, Thr41Ala, Glu62Val, Thr80Ile, 
Thr85Ser) carbenicillin resistance 
This study 
pUT18C – ΔTarP6 
E2H -cya-18 fragment fused to Nterm 100aa TarP L2 
(Ser17Thr, Asn92Asp) carbenicillin resistance 
This study 
pUT18C – ΔTarP7 
E2H -cya-18 fragment fused to Nterm 100aa TarP L2 
(Ser23Thr, Asn69Ile) carbenicillin resistance 
This study 
pUT18C – ΔTarP8 
E2H -cya-18 fragment fused to Nterm 100aa TarP L2 Δ 
(Gln9Leu, Ser32Pro, Thr43Ala, Gln44Leu, Ala71Thr) 
carbenicillin resistance 
This study 
pKT25 - CT043 




Directional TOPO expression vector, kanamycin 
resistance, expressing N-terminus 200aa TARP-HIS 
Brinkworth, 2011 
pET101-Slc2 










Bacterial expression destination vector expressing Scc1-
FLAG 
Brinkworth, 2011 
   
Table 2: Primers used in this study 
Primer Sequence 5’→3’ (restriction enzyme) 
TarP100aa-REV 
                                                       (KpnI) 
GAACTAACGTATGGAGAAAGGTACCCAAGCTTCCAGCAACGGCTT 
TarP100aa-FWD 
                                         (KpnI) 
ATCACCGGTATACGGGTACCGATGATGACGAATTCTATA 
CT043-REV 



























Results and Discussion 
 
Determination of interaction between TarP and Type III 
chaperones from Chlamydia 
 
To evaluate the interaction between TarP and 3 hypothetical T3SS chaperone, 
Slc1, CT088 (Specific Chlamydia Chaperone 1, “Scc1”) and CT663 (Specific 
Chlamydia Chaperone 2, “Slc2”), each target sequence was marked with one of two 
tags. TarP was tagged with 6xHIS-tag, which consists in the addition of 6 histidine 
amino acids before the stop codon. On the other hand, the chaperones were tagged with 
a FLAG-tag, which the sequence is N-DYKDDDDK-C. Reciprocal tagging of TarP and 
chaperones was also performed.  
The TarP insert with the 6xHIS-tag was cloned into Champion™ pET200 
Directional TOPO® from Invitrogen Life Technologies, which is an expression System 
that is designed for high-yield protein production in E. coli. This plasmid encodes for 
resistance to kanamycin antibiotic.  Slc1 and Slc2 with the FLAG-tag were inserted into 
Champion™ pET101 Directional TOPO® from Invitrogen Life Technologies, which 
has the same backbone as pET200 except for the antibiotic resistance cassette, which is 
for ampicillin. Scc1 was cloned into Gateway Nova pET-56-DEST Vector (Millipore). 
This vector is designed to create expression clones that are fused to a C-terminal 
His•Tag This plasmid has an ampicillin resistance cassette. 
The plasmids were transformed into E. coli Top10 and 3 different recombinants 
were made. The first with pET200-TarP200 and pET101-Slc1, the second with pET200-
TarP200 and pET101-Slc2 and the last one with pET200-TarP200 and pET36-DEST-
Scc1 (Brinkworth, 2011).  
 To determine if TarP interacted with the chaperones, pull-down assays were 
performed. Initially, a nickel column (Ni-NTA-agarose, Qiagen) was used to pull-down 
the TarP bait. In the elution fraction, the presence of FLAG-tagged chaperones were 
monitored by Western blotting against the FLAG-tag. Different fractions from the pull-
down experiments were run on SDS-PAGE, transferred to PVDF membranes for 
Western blotting. The chaperone that interacted with 6xHis-TarP should be present in 
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the elution fraction.  In the Figure 2 we can see that the pull-down assay was successful 
because 6xHis-TarP appeared in the lysate and in the elution fractions. The presence of 
TarP in the flow through and washes in two of the membranes could be due to a 
saturation of α-6xHis antibody. It is also clear that, from the three chaperones under 
investigation, only Slc1 interacted with TarP. This chaperone only appeared in the 
elution fraction while Slc2 and Scc1 appeared in the flow through and in the washes 
fractions and are completely absent in the fraction corresponding to the elutions (Figure 
3). 
 
Figure 2: Co-imunoprecipitation, NiNTA agarose beads, α-6xHis. 
NiNTA pull-down of His tag marked protein TarP analysed by Western blot using α-6xHis 
antibody. The bands represented TarP: The top membrane represents the E. coli coexpressing TarP and 







Figure 3: Co-imunoprecipitation, NiNTA agarose beads, α-FLAG. 
NiNTA pull-down of His tag marked proteins TarP analysed by Western blot using α-FLAG 
antibody. The bands represent the different chaperones: The top membrane represents the E. coli 
coexpressing TarP and Slc1; the middle coexpresses TarP and Slc2; the bottom membrane is from the 
clone coexpressing TarP and Scc1. 
 
To confirm this results the inversed pull-down was also made, using the M2-
affinity gel (Sigma). The chaperones marked with FLAG-tag interact with the 
antibodies in the M2-affinity gel. The polyacrylamide gels were analyze again by 
Western blotting with the same antibodies used previously (Figures 4 and 5). We can 
see that these results are concordant with the first pull-down assay. The Figure 4, which 
shows the membranes of the M2 affinity pull-down using α-6xHis antibody, reveals that 
TarP only appears in the elution fraction when it is coexpressed with Slc1. When it is 
coexpressed with Slc2 and Scc1 the Western blot reveal that TarP only appears in the 
Lysate and flow through fractions, and thus not specifically retained in the column. The 




Figure 4: Co-imunoprecipitation, M2 affinity gel, α-6xHis.  
M2 affinity gel pull-down of FLAG tag marked proteins chaperones analysed by Western blot 
using α-6xHis antibody. The bands represent TarP: The top membrane represents the E. coli coexpressing 
TarP and Slc1; the middle coexpresses TarP and Slc2; the bottom membrane is from the clone 
coexpressing TarP and Scc1. 
 
 
In Figure 5, we can confirm that the M2 affinity pull-down assays were done 
correctly showing the majority of the chaperones in the elution fraction with some 
appearing in the flow through and washes but this is probably due to over saturation of 
the affinity gel.  These results were further confirmed using the bacterial two-hybrid 




Figure 5: Co-imunoprecipitation, M2 affinity gel, α-FLAG. 
M2 affinity pull-down of FLAG tag marked proteins chaperones analysed by Western blot using 
α-FLAG antibody. The bands represent the different chaperones: The top membrane represents the E. coli 
coexpressing TarP and Slc1; the middle coexpresses TarP and Slc2; the bottom membrane is from the 
















Determination of binding site between effector TarP and 
chaperone Slc1 
 
Bacteria two-hybrid assay 
This assay is based on a protein encoded by a cyaA gene in Bordetella pertussis, 
which converts ATP to cAMP. Through biochemical studies it was discovered that the 
catalytic domain could be proteolytically cleaved into two complementary fragments 
T25, corresponding to amino acids 1-224, and T18, corresponding to amino acids 245-
399. It was also demonstrated that the two fragments alone were not able to reassociate. 
The rationale behind this method is if the two fragments fused to putative interacting 
proteins were expressed in a adenylate cyclase-deficient E. coli, they would reassociate 
and lead to cAMP synthesis. The function and activity of adenylate cyclase can be 
monitored in E. coli because cAMP binds to a transcriptional activator, CAP, which 
regulates the expression of several genes, including genes involve in the catabolism of 
lactose and maltose (Figure 6) (Karimova, et al. 1998). 
For experimental purposes Karimova, et al. (1998) constructed plasmids that 
expressed either the T25 fragment or the T18. For this study the pUT18C (Annex A2) 
was fused with several sequences of mutant TarP, and pKT25 (Annex A3) fused with 
Slc1.  The mutant sequences of TarP (mTarP) were obtained using random mutagenesis 
by error prone PCR (McCullum, et al. 2010; Pritchard, et al. 2005). Afterwards for the 
isolation of the different sequences they were treated with restriction enzymes, clone 
into pCX340 plasmid, transformed into chemically competent E. coli Top10 and finally 
sent out for sequencing to identify and exclude mutants with frame shift mutations. 
Error prone PCR was optimized by adjusting the Mg
2+
 concentrations a decrease in 
MnCl2, a higher concentration than usual of one of the dNTPs to obtain at least one 
mutation, but no more than six simultaneous mutations within the insert, without 
obtaining frame shift mutations. Random PCR mutagenesis was used instead of site-
directed mutagenesis methods for the following reasons – a) there were no 
distinguishing motifs that could be considered as chaperone binding sites, unlike in 
other pathogens (e.g. Salmonella) (Stebbins and Galân, 2001) and b) single mutations 




Figure 6: Schematic of principle of an E. coli two-hybrid system based on functional 
complementation of CyaA fragments. 
In A, the full-length catalytic domain when expressed in E. coli, exhibits a basal activity that 
results in cAMP synthesis. In B, the two fragments, when coexpressed as independent polypeptides, are 
unable to interact and no cAMP synthesis occurs. In C the two frangements are fused to two interacting 
proteins, X and Y, are brought into close proximity, resulting in functional complementation followed by 
cAMP production. D represents a schematic of promoter activation of the complementation. cAMP, 
synthesized in an E. coli cya strain by the complementing T25 and T18 pairs, binds to the catabolite gene 
activator protein, CAP. The cAMPyCAP complex then can recognize specific promoters such as lacZ and 
mal (Karimova, et al. 1998). 
 
Slc1 protein is highly conserved among chlamydial species. However, there is a 
lack of amino acid similarity amongst the N-termini region of TarPs belonging to 
different Chlamydia species. When analyzing the alignment obtained for the last 200 
amino acids using ClustalW2 Multiple Sequence Alignment of TarP homologs 
belonging to C. trachomatis L2, C. muridarum, GPIC, and C. pneumonia some 
conserved or semi-conserved regions were found. Among these conserved regions 
several spatially conserved hydrophobic sites flanked by conserved threonines and 
serines were found. Furthermore, the previous analysis revealed that the conserved 
regions were located in the N-terminal 100 amino acids of the different TarP homologs, 
which may indicate a possible chaperone binding site. There may be some 




interchangeability involved in the binding of TarP from one species by the Slc1 
chaperone from another, as evidenced by the ability of C. trachomatis Slc1 to 
specifically bind C. caviae TarP (Brinkworth 2011) (Annex A4).   
So in order to determine which amino acid residues were indeed important for 
TarP interaction with the chaperone, we proceeded to the construction of several 
mutants in this region. These mutants were sequence-verified to identify the mutations, 
catalogued, and functionally evaluated using the bacterial two-hybrid assay.  
 
Transformation of E. coli Top10 
The mTarP sequences were kindly provided by Doctor Amanda Brinkworth and 
they were amplified by PCR using an Accuprime PFX polymerase, a DNA polymerase 
with proof reading to avoid further mutations. Afterwards the PCR products were 
purified using a PCR purifying kit. The plasmids were propagated in E. coli Top10, and 
stored at -80ºC. They were extracted using a Miniprep Kit (Qiagen). 
Both the plasmids and the purified inserts were digested using KpnI restriction 
enzyme, which cuts the DNA sequence forming sticky ends. This allows for the 
extremities of the insert and the plasmid to interact and ligate. The digestion was 
followed by PCR purification because KpnI is not deactivated by temperature. The 
mTarP sequences were separately ligated to pUT18C. The agarose gel of cut and uncut 
plasmid analyses is shown in Figure 7 and from it we can assure that the restriction 
enzyme is working properly. Any uncut plasmid could potentially yield false-positive 




Figure 7: Analyzes of pUT18C digestion to confirm the functionality of KpnI. 
Since the plasmid circular DNA in the undigested lane we observe the 3 bands, which is 
common. The top band corresponds to the relaxed circular form, the middle band is when the plasmid is 
linearized, and the bottom band represents the supercoiled circular DNA. In the Digested lane one band 
clearly appears demonstrating a good cleavage by KpnI. 
 
The initial transformation was done in chemically competent cells of E. coli 
Top10. This was due to its high transformation efficiency (1 x 10
9
 cfu/µg supercoiled 
DNA) and is ideal for high-efficiency cloning and plasmid propagation, allowing stable 
replication of high-copy number plasmids. 
The pUT18C plasmid has an Amp
R
 cassette so the transformed E. coli Top10 
bacteria were plated in LB media with carbenicillin. This antibiotic was used instead of 
ampicillin, because it is more stable in solution letting us keep stocks ready for much 
longer periods of time, without having to worry about loss of function. Between 5 to 6 
colonies obtained after the overnight incubation were tested for the presence of the 
insert by colony PCR and analysed by agarose gel electrophoresis. Primers for colony 
PCR immediately flanked the insert.  The results obtained are summarized in Figures 8 
to 14. The DNA band of the positive colonies is around the 300 bp mark, which is 




Figure 8: mTarP 1 confirmation in E. coli Top10.  
Analysis of E. coli Top10 for the presence of pUT18C plasmid with mTarP, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE Legend: mTarP 1* - positive result for the presence of the 
insert; mTarP 1 - negative result for the presence of the insert. The lower band are background bands. 
 
Figure 9: mTarP 2 confirmation in E. coli Top10.  
Analysis of E. coli Top10 for the presence of pUT18C plasmid with mTarP 2, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE. Legend: mTarP 2* - positive result for the presence of the 
insert; mTarP 2 - negative result for the presence of the insert. 
 
Figure 10: mTarP 3 and 4 confirmation in E. coli Top10.  
Analysis of E. coli Top10 for the presence of pUT18C plasmid with mTarP 3 and plasmid with 
mTarP 4, in the case of mTarP 4, using primers TarP100aa-FW and TarP100aa-REV (Table 2). 
Amplification products were resolved in 1,5% agarose gel and visualized by staining with SYBR SAFE. 
Legend: mTarP 3* - positive result for the presence of the insert; mTarP 3 - negative result for the 
presence of the insert; mTarP 4*- positive result for the presence of the insert; mTarP 4- negative result 




Figure 11: mTarP 5 confirmation in E. coli Top10. 
Analysis of E. coli Top10 for the presence of pUT18C plasmid with plasmid with mTarP 5, 
using primers TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 
1,5% agarose gel and visualized by staining with SYBR SAFE Legend: mTarP 5* - positive result for the 
presence of the insert; mTarP 5 - negative result for the presence of the insert. 
 
Figure 12: mTarP 6 confirmation in E. coli Top10. 
Analysis of E. coli Top10 for the presence of pUT18C plasmid with mTarP 6, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE Legend: mTarP 6*- positive result for the presence of the 
insert; mTarP 6 - negative result for the presence of the insert. 
 
Figure 13: mTarP 7 confirmation in E. coli Top10.  
Analysis of E. coli Top10 for the presence of pUT18C plasmid with mTarP 7, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE Legend: mTarP 7* - positive result for the presence of the 




Figure 14: mTarP 8 confirmation in E. coli Top10.  
Analysis of E. coli Top10 for the presence of pUT18C plasmid with mTarP 8, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE Legend: mTarP 8* - positive result for the presence of the 
insert. 
 
The positive colonies were grown overnight, and part of this culture was stored 
at -80 ºC with 30% glycerol as stocks. The rest was used to extract the plasmid using the 
Qiagen miniprep kit and sent for sequencing, using the TarP100aa-REV primer, to 
ascertain if no further mutations were added, because of the PCR amplification reaction, 
which could lead to frame shift mutation. Another reason to do this procedure was to 
assure that the insert was fused in the right direction within the plasmid. This was 
verified using the BLAST nucleotide alignment tool to assure that prior to the TarP 
gene there was the cya gene from Bordetella (data not shown). 
In the Figures 8 to 14, only the mTarP sequences, which were proven to have the 
insert in the right location and orientation, are shown. 
 
Transformation of E. coli DHM1 
The pKT25 plasmid was fused with hypothetical type III chaperone CT043 and 
electroporated into E. coli DHM1. The non-mutated N-terminous 100 amino acids of 
TarP was also fused to pUT18C, and electroporeted into E. coli DHM1 pKT25-Slc1 to 
serve as a positive control for the bacterial two-hybrid assay done by Amanda 
Brinkworth. 
The mTarP 1 to 8 that were previously transformed into E. coli Top 10 were 
extracted using the miniprep kit from Qiagen and electroporated into electrocompetent 
E. coli DHM1 with pKT25-Slc1 plated in LB agar with carbenicillin and kanamycin. 
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Like the previous transformation 5 to 6 colonies obtained were analysed by colony PCR 
to confirm the presence of the Slc1 (Figure 15) as well as mTarP inserts (Figures 16 to 
22). 
 
Figure 15: Slc1 confirmation in E. coli DHM1.  
Analysis of E. coli DHM1 for the presence of pKT25 plasmid with Slc1, using primers      
CT043-FW and CT043-REV (Table 2). Amplification products were resolved in 1,5% agarose gel and 
visualized by staining with SYBR SAFE Legend: Slc1 – example of two positive result for the presence 
of the Slc1 insert. 
 
Figure 16: mTarP 1 confirmation in E. coli DHM1.  
Analysis of E. coli DHM1 for the presence of pUT18C plasmid with mTarP 1, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE Legend: mTarP 1 - positive result for the presence of the 
insert. 
 
Figure 17: mTarP 2 confirmation in E. coli DHM1.  
Analysis of E. coli DHM1 for the presence of pUT18C plasmid with mTarP 2, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 





Figure 18: mTarP 3 confirmation in E. coli DHM1. 
Analysis of E. coli DHM1 for the presence of pUT18C plasmid with mTarP 3, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE Legend: mTarP 3 - positive result for the presence of the 
insert. 
 
Figure 19: mTarP 4 and 5 confirmation in E. coli DHM1. 
Analysis of E. coli DHM1 for the presence of pUT18C plasmid with mTarP 4 and plasmid with 
mTarP 5, using primers TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were 
resolved in 1,5% agarose gel and visualized by staining with SYBR SAFE Legend: mTarP 4 - positive 
result for the presence of the insert; mTarP 5 - positive result for the presence of the insert. 
 
Figure 20: mTarP 6 confirmation in E. coli DHM1.  
Analysis of E. coli DHM1 for the presence of pUT18C plasmid with mTarP 6, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 





Figure 21: mTarP 7 confirmation in E. coli DHM1.  
Analysis of E. coli DHM1 for the presence of pUT18C plasmid with mTarP 7, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE Legend: mTarP 7 - positive result for the presence of the 
insert. 
 
Figure 22: mTarP 8 confirmation in E. coli DHM1.  
Analysis of E. coli DHM1 for the presence of pUT18C plasmid with mTarP 8, using primers 
TarP100aa-FW and TarP100aa-REV (Table 2). Amplification products were resolved in 1,5% agarose gel 
and visualized by staining with SYBR SAFE Legend: mTarP 8 - positive result for the presence of the 
insert. 
 
Analysis of mTarP sequences. 
The analyses of mTarP sequences was done using the software Geneious Basic 
5.4.4 program, which allows the alignment and comparison between the different 
sequences with a reference sequence in this case it was the first 100 amino acids of      
C. trachomatis serovar L2 TarP. The software also provides a graphic figure showing 
the hydrophobicity of each amino acid allowing for an easy comparison, of the 
hydrophobicity changes, between the mutants and the reference sequence (Figure 24).  
Sequence analysis was followed by bacterial two-hybrid assay to functionally evaluate 
the effects of the mutations on Slc1 interaction with TarP. 
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Bacteria two-hybrid assay was performed using the eight colonies mentioned 
above.  LB plates supplemented with antibiotics carbenicillin and kanamycin were used 
to prevent the growth of contaminants and the loss of both plasmids. IPTG and X-gal 
were also added to the medium. IPTG is used to induce the expression from the ptac 
promoter that regulates the expression in both plasmids of the cya fragment fused with 
the proteins of interest (T18-mTarP and T25-Slc1). X-gal is an indicator of                    
-galactosidase activity, which should increase if there was induction of lacZ 
expression. lacZ expression should only occur if the two subunits of cya were 
reconstituted by virtue of interaction between the two fused proteins. The interaction is 
detected by the development of blue colonies. In Figure 23 it is possible to see the result 
for this assay. 
 
Figure 23: Bacterial two-hybrid assay.  
Colonies mark 1-8 represent the E. coli DHM1 transformed with pUT18C.mTarP 1 to 8 
respectably and pKT25-Slc1; the colony marked as TarP has the plasmids pUT18C-TarP, and pKT25-
Slc1; The colony marked as empty has both the pUT18C and pKT25 with no inserts. 
 
As we can see mTarP 1 only has two different amino acid substitutions from a 
serine to a threonine (Ser17Thr, Ser23Thr). Analysing the hydrophobicity chart we can 
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see that the difference in hydrophobicity is not significant, which means that if the 
binding between TarP and Slc1 was due to hydrophobic interactions the colonies colour 
should resemble the positive control. 
In the mTarP 2 sequence there are six amino acid substitution mutations at 
residues 9, 26, 39, 56, 57, and 66. On one hand, we have the mutation from a glutamine 
to a histidine (Gln9His), which as can be seen in the figure, does not alter significantly 
the hydrophobicity. One mutation decreased the hydrophobicity in position 57 by 
substituting the amino acid isoleucine to asparagine (Ile57Asn). On the other hand, 
there are the mutations that changed serine to tyrosine (Ser26Tyr), asparagine to 
isoleucine (Asn39Ile, Asn66Leu), and serine to proline (Ser56Pro), which together 
greatly increase the overall hydrophobicity of the protein, which in theory should 
strengthen the binding between mTarP and Slc1. From such a more stable binding, one 
would expect colonies on X-gal plates with similar colouration as that of wild-type. 
However, this is not the case. The colony had less blue colour than the wild-type 
colony, but had a slightly higher blue colouration when compared to the negative 
control.  This result indicates that together, the mutations slightly affected binding of 
Slc1 to mTarP 2.  A similar colony phenotype was observed for mTarP 3.  Two amino 
acid substitution mutations are present in mTarP 3. The first is a change from glutamine 
to leucine (Gln44Leu) and the other one from threonine to alanine (Thr68Ala). The 
Gln44Leu change greatly increased the hydrophobicity and Thr68Ala slightly increases 
it as well. So the expected result would be a colony colour similar to the positive control 
or a darker colour due to a stronger binding.  As with mTarp 2, the binding was less 
efficient that wild-type or mTarP 1. The mTarP 4 mutant has the same mutation in the 
amino acid 44 that mTarP 3 and the expected results should be the same.  The results 
for mTarP 2, 3, and 4 could mean that increasing the overall hydrophobicity of the first 
100 amino acid residues may have a negative effect on Slc1 binding.  On the other 
hand, some of the six mutations may have hit residues essential for Slc1 binding, thus 
giving an intermediate phenotype.  
The mTarP 5 and 8 mutants had multiple mutations.  Sequencing of the inserts 
revealed six amino acid substitution mutations (amino acids 13, 21, 41, 62, 80, 85) for 
mTarP 5 and five for mTarP 8 at positions 9, 32, 43, 44, and 71. Four of those mutations 
in mTarP 5 do not change significantly the hydrophobicity of the overall protein, those 
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mutations are: from a threonine to a serine (Thr13Ser; Thr85Ser), from a serine to 
threonine (Ser21Thr) and from a threonine to alanine (Thr41Ala). The other mutations 
significantly increased the hydrophobicity of the protein, namely a glutamine-to-valine 
change (Glu62Val) and a threonine to isoleucine (Thr80Ile) substitution. A similar 
predicted increase in net hydrophobicity could be inferred from the amino acid sequence 
of mTarP 8. Two mutations Thr43Ala and an Ala71Thr substitution did not result in an 
increase in hydrophobicity, but when combined with other substitutions (i.e. from a 
glutamine to a leucine (Gln9Leu) at position 9, an alanine to a proline (Ser32Pro) and a 
glutamine to a leucine (Gln44Leu)), a predicted net increase in hydrophobicity is 
apparent. Therefore, similar to mTarP 2, 3, and 4, it was  not possible to distinguish if 
the decreased interaction of Slc1 with these mutants could be attributed to an increase in 
net hydrophobicity or the changes to essential amino acid residues.   
Two mutants that were informative were mTarP 6 and mTarP 7, whose 
phenotypes did not seem to be associated with increased hydrophobicity, unlike mTarP 
2, 3, 4, 5 and 8. Two amino acid substitutions were observed in the m TarP 6. One is a 
serine to a threonine (Ser17Thr) substitution and the other was an asparagine to an 
aspartic acid (Asn92Asp) substitution. Both mutations did not significantly change the 
protein hydrophobicity. The same could be said for mTarP 7 mutations, which consisted 
of a serine-to-threonine (Ser23Thr) and an asparagine-to-tyrosine (Asn69Ile) 
substitution. Their respective colonies displayed intermediate phenotypes, indicating 
that Ser17, Asn92, Ser 23, and Asn69 may be essential for Slc1 binding. 
Taken together, it is possible that TarP may rely on both specific sequences, and 





Figure 24: Sequences of mTarP.  
mTarP sequences were compared with the reference sequence from C. trachomatis serovar L2 
TarP, with the mutations highlighted. Underneath each sequence there is a graphic, which represents the 







A characteristic of many bacterial T3S effectors is their need of a specific 
chaperone for efficient secretion into the host cell cytosol (Knodler, et al., 2006). Most 
chaperones bind only to one, or a maximum of two effector with some sequence 
similarities, the exception being Spa15 from S. flexneri, which was found to be able to 
bind with several effectors with no sequence similarity (Page, et al., 2001; Page and 
Parsot, 2002). 
Is this project, it was found using pull-down assays that chaperone Slc1 interacts 
with chlamydial effector TarP, one of the first effectors to be secreted and essential for 
the invasion of Chlamydia into the host cell (Clifton et al., 2004; Clifton et al., 2005). 
Interestingly, the other two putative chaperones present in EBs did not bind TarP, 
indicating that amino acids 1-100 has the necessary sequence information to confer 
specific interaction with Slc1 and not with the structurally homologous Slc2 and Scc1 
proteins.  To investigate this specificity, we undertook a random mutagenesis 
experiment to introduce mutations within TarP (1-100). Using the bacteria two-hybrid 
assay, the mutated derivatives were evaluated for their abilities to interact with Slc1 in a 
prokaryotic cytosolic milieu.  Data indicated that binding of Slc1 to TarP may be 
determined by both general hydrophobic interactions and specific amino acids.  This 
work provided the first report of a systematic investigation of the interaction between an 
EB-associated effector (TarP), with its recently identified chaperone Slc1.  This avenue 
of research is important as an optimal interaction is likely required for efficient 
translocation of the effector from the bacterial cytosol into the host cell cytoplasm, as 
recently demonstrated using a heterologous T3SS (Brinkworth 2011). 
The co-imunoprecipitation experiments, which were successful in demonstrating 
TarP interaction with Slc1 involved the co-expression of both chaperone and effector.  
This is particularly important as it mimics the potential environment within the 
reticulate body, where TarP and Slc1 are co-expressed prior to RB-to-EB 
differentiation.  Therefore, we can confidentially say that the specificity of TarP for 
Slc1 displayed in this experimental system accurately reflects the true situation in 
Chlamydia.  Also, the interaction was more efficient when compared with pre-purified 
components mixed in vitro (Brinkworth, 2011).  In addition, co-expression allows for 
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the co-translational interaction between newly made Slc1 proteins with the growing 
polypeptide chain of TarP as it emerges from the ribosome.  It is possible that under this 
condition, like with other Type III effectors, the N-terminal end could be maintained in 
a relatively disorganised conformation, which in turn may promote chaperone binding 
by exposing the hydrophogic residues, as well as critical amino acid side chains.   
The characterization of this chaperone-effector binding was investigated using a 
bacterial two-hybrid system to evaluate eight mutant sequences of TarP. Five of these 
sequences (mTarP 2, 3, 4, 5 and 8) had mutations, which greatly increased the net 
hydrophobicity of the polypeptide. These revealed an intermediate phenotype (i.e. the 
blue coloration was significantly less than the wild-type, but noticeably greater than the 
negative control) suggesting that either one or more mutations in these mutants were in 
amino acids essential for the interaction between TarP and Slc1 or that the net increase 
in hydrophobicity had a negative effect in this interaction. The other three mutants 
(mTarP 1, 6 and 7) showed no significant differences in the overall hydrophobicity of 
the protein relative to the wild-type sequence, yet they presented an intermediate 
phenotype suggesting that the partial loss of binding could be attributed not to effects on 
hydrophobicity, but to mutations that possibly targeted essential amino acids for the 
interaction. One particular mutation in mTarP 6 (Asn92Glu) involved a change from a 
polar and uncharged side chain to a polar acidic one.  This change could affect local 
hydrogen bonding of neighbouring residues with this new side chain. Interestingly, both 
mTarP 6 and 7 displayed Ser-to-Thr substitution.  Other mutants also displayed such 
changes, but it was difficult to ascribe altered functions because of the other mutations 
that significantly changed hydrophobicity.  However, in the context of the other 
mutations in mTarP 6 and 7, without the confounding effects of changes in net 
hydrophobicity, these Ser-to-Thr substitutions may indicate that Ser residues may be 
necessary for Slc1 binding to TarP. Indeed, one of the common features within the 
otherwise relatively variable N-terminal region amongst the different TarP homologs is 
the presence of a number of serine residues. Thus it is possible that serine in some or all 
of these positions are necessary, and even a conservative substitution of Ser to Thr 
could not be tolerated.  Thus, it may be worth investigating, using the same bacterial 




It is known that SptP, a Yersinia class I T3S chaperones interact with its effector 
YopE using two types of interactions, hydrophobic, which provide the binding strength, 
and hydrogen bonds, which is believed to provide specificity to between the chaperone-
effector (Ghosh, 2004). Thus, it is possible that some of the residues targeted in the 
mutagenesis experiments form crucial hydrogen bonds with Slc1 amino acid residues, 
and by substituting these residues for different ones, as in mTarP 6, altered hydrogen 
bonds that are not compatible with Slc1/TarP interaction are formed and thereby 
diminishing the interaction, which manifests as intermediate phenotypes in the bacterial 
two-hybrid assay. One of the potential pitfalls of mutagenesis experiments is the effect 
on protein conformation, which in turn would be expected to dramatically affect the 
quality of protein-protein interactions.  However, this may not be applicable in this 
particular case because a number of studies have shown that the N-terminus region of 
other effectors tended to remain in a disorganised conformation.  This disorganisation 
may allow the docking of a relatively linear polypeptide into the hydrophobic groove 
formed by the dimerisation of two chaperone molecules (Yip and Strynadka, 2006). 
To our knowledge, this is the first attempt to identify the nature of chaperone 
binding site on TarP.  With this knowledge, we advance the efforts to define the 
















To confirm the results obtained in this project a β-galactocidase assay would be 
appropriate because it would give a more objective result measured in Miller units, 
which could be more easily compared with each other as well as giving statistical 
results. Also, after confirming these mutants decrease in binding the mutations should 
be tested individually to determine the extent of contribution to the loss of binding.  
This would also allow for a more systematic analysis of the effects of different 
combinations of mutations.  These studies could also be extended to translocation 













A1: Secondary structure alignment of type III chaperones. 
Three C. trachomatis proteins share predicted secondary structural features characteristic of 
known type III export chaperones. Primary amino acid sequence alignment of known type III export 
chaperones CesT (Enteropathogenic E. coli, EPEC), SycE (Y. enterocolitica) and SicP (S. enterica 
serovar typhimurium) with the putative export chaperones Slc1 (CT043), Slc2 (CT663) and Scc1 (CT088) 
of C. trachomatis. Secondary structure was predicted using Jpred and sequences aligned manually to 
according to the α-β-β-β-α-β-β-α signature characteristic of some type III export chaperones. Residues 















A2: Diagram of the pUT18C vector (Brinkworth, 2011). 
 
 










 AbdelRahman Y. M., Belland, R. J. 2005. The chlamydial developmental cycle. 
FEMS Microbiology Reviews. 29: 949-959. 
 Brinkworth, A. J., 2011. Identification and biochemical characterization of the 
chlamydia trachomatis type III secretion chaperone, Slc1, and its role in the 
translocation of the invasion associated effector TarP [Ph. D. dissertation]. 
University of Louisville. Louisville, Kentucky. pp 100 (in print). 
 Büttner D., Bonas U. 2002. Port of entry – The type III secretion Translocon. 
Trends in Microbiology. 10(4): 186-192. 
 Carabeo R. A., Dooley C. A., Grieshaber S. S., Hackstadt T. 2007 Rac interacts 
with Abi-1 and WAVE2 to promote an Arp2/3-dependent actin recruitment 
during chlamydial invasion. Cellular Microbiology. 9(9): 2278-2288. 
 Clifton D. R., Fields K. A., Grieshaber S. S., Dooley C. A., Fischer E., Mead D., 
Carabeo R. A., Hackstadt T. 2004. A chlamydial type III translocated protein is 
tyrosine phosphorylated at the site of entry and associated with recruitment of 
actin. Proceedings of the National Academy of Science of the United States of 
America. 101: 10166–10171. 
 Clifton D. R., Dooley C. A., Grieshaber S. S., Carabeo R. A., Fields K. A., 
Hackstadt T. 2005. Tyrosine phosphorylation of the chlamydial effector protein 
Tarp is species specific and not required for recruitment of actin. Infection and 
Immunity. 73: 3860–3868. 
 Cornelis, G. 2006. The Type III Secretion Injectisome. Nature. 4:811-824. 
 Darville, T., Hiltke, T. J. 2010. Pathogenesis of genital tract disease due to 
Chlamydia trachomatis. Journal of Infectious Disease. 201 Suppl 2: 114-25. 
 Elwell, C. A., Ceesay, A., Kim, J. H., Kalman, D., Engel, J. 2008. RNA 
Interference Screen Identifies Abl Kinase and PDGFR Signaling in  Chlamydia 
trachomatis Entry. PLOS Pathogens. 4(3).  
 European Centre for Disease Prevention and Control. 2010. Annual 
Epidemiological Report on Communicable Diseases in Europe 2010. ECDC. 





 Fields, K. A., Mead, D. J., Dooley, C. A. and Hackstadt, T. 2003. Chlamydia 
trachomatis type III secretion: evidence for a functional apparatus during early-
cycle development. Molecular Microbiology. 48: 671–683. 
 Ghosh P. 2004. Process of protein transport by the type III secretion system. 
Microbiology and Molecular Biology Reviews. 68(4): 771-95. 
 Karimova, G., Pidoux, J., Ullmann, A., Ladant, D. 1998. A bacterial two-hybrid 
system based on a reconstituted signal transduction pathway. Proceedings of the 
National Academy of Science of the United States of America 95: 5752-5756. 
 Kim, J.F., 2001. Revisiting the chlamydial type III protein secretion system: 
clues to the origin of type III protein secretion. Trends in Genetics. 17(2): 65-69. 
 Knodler, L. A., Bertero, M., Yip, C., Strynadka, N. C. J., Steele-Mortimer, O. 
2006. Structure-based mutagenesis of SigE verifies the importance of 
hydrophobic and electrostatic residues in type III chaperone function. Molecular 
Microbiology. 62(4): 928-40. 
 Jewett, T. J., Fischer, E. R., Mead. D. J., Hackstadt T. 2006. Chlamydial TARP 
is a bacterial nucleator of actin. Proceedings of the National Academy of 
Science of the United States of America 103: 15599–15604. 
 Jewett, T. J., Dooley, C. A., Mead, D. J., Hackstadt, T. 2008. Chlamydia 
trachomatis tarp is phosphorylated by src family tyrosine kinases. Biochemical 
and Biophysical Research Communications 371: 339–344. 
 Lane B. J., Mutchler C., Al Khodor S., Grieshaber S. S., Carabeo R. A. 2008. 
Chlamydial Entry Involves TARP Binding of Guanine Nucleotide Exchange 
Factors. PLOS Pathogens. 4(3). 
 McCullum, E. O., Williams, B. A. R., Zhang, J., Chaput, J. C. 2010. Random 
Mutagenesis by Error-Prone PCR. In: In Vitro Mutagenesis Protocols: Third 
Edition. (Ed. Braman, J.) Methods in Molecular Biology, 634. 
  Mehlitz, A., Banhart S., Hess S., Selbach M., Meyer T. F. 2008. Complex 
kinase requirements for Chlamydia trachomatis Tarp phosphorylation. FEMS 
Microbiology Letters, 289: 233-240. 
 Mehlitz, A., Banhart, S. Mäurer, A. P., Kaushansky, A., Gordus, A. G., Zielecki, 
J., MacBeath, G., Meyer, T. F. 2010. Tarp regulates early Chlamydia-induced 
xxii 
 
host cell survival through interactions with the human adaptor protein SHC1. 
Journal of Cell Biology. 190(1): 143-57. 
 Moulder, J.W. 1991. Interaction of Chlamydiae and host cells in vitro. 
Microbiology Reviews 55: 143–190. 
 Page, A.L., Fromont-Racine, M., Sansonetti, P., Legrain, P., and Parsot, C. 
2001. Characterization of the interaction partners of secreted proteins and 
chaperones of Shigella flexneri. Molecular Microbiology. 42: 1133-1145. 
 Page A. L., Parsot, C. 2002. Chaperones of the type III secretion pathway: jacks 
of all trades. Molecular Microbiology 46(1): 1-11. 
 Peters, J., Wilson, D. P., Myers, G., Timms, P., Bavoil, P. M. 2007. Type III 
secretion à la Chlamydia. Trends in Microbiology. 15(6): 241-251. 
 Pritchard, L., Corne, D., Kell, D., Rowland, J., Winson, M. 2005. A general 
model of error-prone PCR. Journal of Theoretical Biology. 234(4): 497-509 
 Schachter J. 1999. Infection and Disease Epidemiology. pp. 139-169. In: 
Chlamydia: intracellular biology, pathogenesis, and immunity (Ed., R. S. 
Stephens). American Society for Microbiology. United States of America. 
 Stebbins C. E., Galán J. E. 2001. Maintenance of an unfolded polypeptide by a 
cognate chaperone in bacterial type III secretion. Nature. 414: 77-81. 




 Yip, C.K., Strynadka, N.C. 2006. New structural insights into the bacterial type 
III secretion system. Trends in Biochemical Science,. 31(4): 223-30. 
 
 
